Genmab A/SGMABNASDAQ
Loading
Operating Income ScalingExpanding
Percentile Rank100
3Y CAGR+8.4%
5Y CAGR+4.8%
Studio
Year-over-Year Change

Profit from core business operations before interest and taxes

3Y CAGR
+8.4%/yr
vs +46.0%/yr prior
5Y CAGR
+4.8%/yr
Recent acceleration
Acceleration
-37.6pp
Decelerating
Percentile
P100
Near historical high
vs 5Y Ago
1.3x
Solid growth
Streak
2 yr
Consecutive growthExpanding
PeriodValueYoY Change
2025$7.97B+18.9%
2024$6.70B+26.0%
2023$5.32B-15.1%
2022$6.27B+112.2%
2021$2.95B-53.2%
2020$6.31B+139.3%
2019$2.64B+91.1%
2018$1.38B+2.7%
2017$1.34B+27.7%
2016$1.05B-